JP4729503B2 - 抗癌剤の奏効率増強剤 - Google Patents

抗癌剤の奏効率増強剤 Download PDF

Info

Publication number
JP4729503B2
JP4729503B2 JP2006551137A JP2006551137A JP4729503B2 JP 4729503 B2 JP4729503 B2 JP 4729503B2 JP 2006551137 A JP2006551137 A JP 2006551137A JP 2006551137 A JP2006551137 A JP 2006551137A JP 4729503 B2 JP4729503 B2 JP 4729503B2
Authority
JP
Japan
Prior art keywords
cancer
anticancer
chemotherapy
agent
donor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2006551137A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501630A (ja
JP2008501630A6 (ja
Inventor
浩康 安田
睦雄 山谷
勝敏 中山
英忠 佐々木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Kayaku Co Ltd
Original Assignee
Nippon Kayaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Kayaku Co Ltd filed Critical Nippon Kayaku Co Ltd
Priority to JP2006551137A priority Critical patent/JP4729503B2/ja
Publication of JP2008501630A publication Critical patent/JP2008501630A/ja
Publication of JP2008501630A6 publication Critical patent/JP2008501630A6/ja
Application granted granted Critical
Publication of JP4729503B2 publication Critical patent/JP4729503B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2006551137A 2004-06-10 2005-06-10 抗癌剤の奏効率増強剤 Expired - Lifetime JP4729503B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006551137A JP4729503B2 (ja) 2004-06-10 2005-06-10 抗癌剤の奏効率増強剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004173174 2004-06-10
JP2004173174 2004-06-10
JP2006551137A JP4729503B2 (ja) 2004-06-10 2005-06-10 抗癌剤の奏効率増強剤
PCT/JP2005/011078 WO2005120493A1 (en) 2004-06-10 2005-06-10 Anticancer effect enhancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011047781A Division JP2011144190A (ja) 2004-06-10 2011-03-04 抗癌剤の効果増強剤

Publications (3)

Publication Number Publication Date
JP2008501630A JP2008501630A (ja) 2008-01-24
JP2008501630A6 JP2008501630A6 (ja) 2008-05-29
JP4729503B2 true JP4729503B2 (ja) 2011-07-20

Family

ID=34970391

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006551137A Expired - Lifetime JP4729503B2 (ja) 2004-06-10 2005-06-10 抗癌剤の奏効率増強剤
JP2011047781A Pending JP2011144190A (ja) 2004-06-10 2011-03-04 抗癌剤の効果増強剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011047781A Pending JP2011144190A (ja) 2004-06-10 2011-03-04 抗癌剤の効果増強剤

Country Status (8)

Country Link
US (2) US20080039521A1 (enExample)
EP (1) EP1778215B1 (enExample)
JP (2) JP4729503B2 (enExample)
KR (1) KR20070045187A (enExample)
CN (1) CN101001623B (enExample)
DE (1) DE602005018222D1 (enExample)
ES (1) ES2338022T3 (enExample)
WO (1) WO2005120493A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1888510A4 (en) 2005-05-27 2013-01-16 Univ North Carolina NITROGEN OXIDE-RELATED PARTICLES FOR NITROGEN OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS
JP2010024170A (ja) * 2008-07-17 2010-02-04 Hiroshi Maeda 抗悪性腫瘍剤の腫瘍組織への局所送達増強剤
EP2334279A4 (en) * 2008-10-16 2013-03-20 Novan Inc STAIN OXIDE RELEASING PARTICLES FOR MOUTH CARE APPLICATIONS
US9072688B2 (en) * 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100111857A1 (en) 2008-10-31 2010-05-06 Boyden Edward S Compositions and methods for surface abrasion with frozen particles
US20100111834A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US9060931B2 (en) * 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8551506B2 (en) * 2008-10-31 2013-10-08 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8762067B2 (en) * 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US8793075B2 (en) * 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8849441B2 (en) * 2008-10-31 2014-09-30 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8731841B2 (en) * 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8721583B2 (en) * 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US20100111831A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for surface abrasion with frozen particles
US9050317B2 (en) * 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8731840B2 (en) * 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8725420B2 (en) * 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8731842B2 (en) * 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US9050070B2 (en) * 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8603495B2 (en) * 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8784384B2 (en) * 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Frozen compositions and array devices thereof
US9060934B2 (en) * 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9060926B2 (en) * 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9056047B2 (en) 2008-10-31 2015-06-16 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8788211B2 (en) * 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US9072799B2 (en) * 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US20100111836A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US20100111835A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
US20100111845A1 (en) * 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with frozen particles
DK2467173T3 (da) 2009-08-21 2019-07-29 Novan Inc Sårbandager, fremgangsmåder til anvendelse heraf og fremgangsmåder til dannelse deraf
ES2958410T3 (es) 2009-08-21 2024-02-08 Novan Inc Geles tópicos
US20110086234A1 (en) * 2009-10-13 2011-04-14 Nathan Stasko Nitric oxide-releasing coatings
CN102107009A (zh) * 2009-12-25 2011-06-29 奇复康药物研发(苏州)有限公司 天然药物组分和一氧化氮供体的混合复方药物及其用途
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118819A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
JP5842367B2 (ja) * 2011-04-07 2016-01-13 ニプロ株式会社 抗癌剤増感剤
WO2012154975A2 (en) * 2011-05-11 2012-11-15 Stc.Unm Nitric oxide/cgmp pathway inhibition of vla-4 related cell adhesion
CN103130815B (zh) * 2013-02-07 2015-10-07 浙江工业大学 一种单硝酸异山梨酯衍生物及其制备方法和应用
EP3108890B1 (en) 2014-02-20 2022-12-28 Hirofumi Yamamoto Enhancer of anti-tumor effect of anti-cancer agent
WO2015133522A1 (ja) 2014-03-04 2015-09-11 国立大学法人大阪大学 大腸癌の治療剤、及び大腸癌患者の予後の予測方法
EP3195168B1 (en) * 2014-07-31 2022-09-07 The University Of Western Australia A method for the identification of immunotherapy-drug combinations using a network approach
CN107823644B (zh) * 2017-11-07 2021-03-02 福州大学 一种no供体化合物在制备抑制富含巯基分子的肿瘤细胞的侵袭和转移能力药物中的应用
CN109498818B (zh) * 2018-05-25 2021-08-31 福州大学 一种产生NO的pH敏感脂质体及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010267A1 (en) * 1993-10-08 1995-04-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers
CA2246734A1 (en) * 1996-02-20 1997-08-21 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers
IT1282686B1 (it) * 1996-02-26 1998-03-31 Nicox Sa Composti in grado di ridurre la tossicita' da farmaci
JP2003523965A (ja) 2000-01-26 2003-08-12 シーダース シナイ メディカル センター 異常な脳領域および／または悪性腫瘍に薬剤をデリバリーするためにカリウムチャンネルアゴニストを使用する方法
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20020173538A1 (en) * 2000-06-30 2002-11-21 Ming-Shi Shiao Method for sensitizing cancer cells to cancer therapies with a mevalonate-reducing compound
JP2005527510A (ja) * 2002-03-06 2005-09-15 セレジー ファーマシューティカルズ インコーポレーティッド 癌の治療において一酸化窒素模倣体を使用するための製剤および方法

Also Published As

Publication number Publication date
CN101001623B (zh) 2010-11-17
EP1778215B1 (en) 2009-12-09
ES2338022T3 (es) 2010-05-03
EP1778215A1 (en) 2007-05-02
DE602005018222D1 (enExample) 2010-01-21
JP2011144190A (ja) 2011-07-28
US20080039521A1 (en) 2008-02-14
JP2008501630A (ja) 2008-01-24
US8410175B2 (en) 2013-04-02
WO2005120493A1 (en) 2005-12-22
US20090137683A1 (en) 2009-05-28
WO2005120493A8 (en) 2007-03-22
CN101001623A (zh) 2007-07-18
KR20070045187A (ko) 2007-05-02

Similar Documents

Publication Publication Date Title
JP4729503B2 (ja) 抗癌剤の奏効率増強剤
JP2008501630A6 (ja) 抗癌剤の効果増強剤
Dillon et al. PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours
Ajani et al. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma
US12102613B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
Kelley et al. Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206
Filis et al. Breakthrough in RAS targeting with pan-RAS (ON) inhibitors RMC-7977 and RMC-6236
Jansen et al. Postoperative chemoradiotherapy in gastric cancer––a phase I–II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapy
Garattini et al. Perspectives in cancer chemotherapy
William Jr et al. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer
Jeremić et al. Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients
Kubota et al. Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer
Nomura et al. Phase II study of preoperative concurrent chemoradiation therapy with S-1 in patients with T4 oral squamous cell carcinoma
Jackson et al. Therapeutic options in gastric cancer: neoadjuvant chemotherapy vs postoperative chemoradiotherapy
Garces et al. Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer
Czito et al. A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma
Mitsis et al. Exceptional clinical response to BRAF-targeted therapy in a patient with metastatic sarcoma
Zhang et al. The Role of Radiosensitizing Drugs in Osteosarcoma Treatment: Mechanisms and Clinical Perspectives
Pergolizzi et al. Induction chemotherapy to weekly paclitaxel concurrent with curative radiotherapy in stage IV (M0) unresectable head and neck squamous cell carcinoma: a dose escalation study
Venate et al. Exploring the therapeutic synergism of Vardhamana Pippali Rasayana with a standard of care in nonsmall cell lung cancer
Solanki et al. Theranostic Approaches for Combating Cancers
Vyas et al. A Case Study and Literature Review: Adenocarcinoma of the Lung
Patel Systemic therapy for advanced soft-tissue sarcomas
Darrah et al. Metastatic Pancreatic Cancer with BRAF and P53 Mutations: Case Report of Therapeutic Response to Doublet Targeted Therapy
Seo et al. A phase II study of paclitaxel and cisplatin as salvage therapy for patients with advanced or metastatic gastric cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110304

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110405

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110418

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140422

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070516

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070516

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070312

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250